Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Moderna’s coronavirus vaccine candidate shows promise in phase I trial

Moderna, who partnered with the National Institutes of Health, announced that its candidate vaccine appeared to be safe when administered to eight healthy volunteers. The vaccine also stimulated an immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).

20 May 2020

Countries that develop a coronavirus vaccine may not share it, health expert warns

The pandemic has sparked a worldwide race to develop a vaccine against the novel coronavirus. But a health expert has warned that the world might face a risk of "vaccine nationalism," wherein countries who will produce a coronavirus vaccine will not share it with others.

20 May 2020

Researchers describe new methods to speed up drug approvals during pandemics

In response to the COVID-19 pandemic, researchers from the Massachusetts Institute of Technology have published a pair of studies in a COVID-19 special issue of the Harvard Data Science Review, freely available via open access, describing new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines and other anti-infective therapies.

20 May 2020

Aerosol transmission through new vs. reused N95 masks

The world is grappling with the worst pandemic in over 100 years. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus which emerged in China in December 2019 but has now spread across the globe. With a rapid rate of transmission, SARS-CoV-2 has now affected over 4.88 million people and resulted in over 322,000 deaths.

19 May 2020

The use of rheumatoid arthritis drug sarilumab in severe COVID-19 pneumonia

A new study published on the preprint server medRxiv* in May 2020 reports the beneficial effects of the monoclonal antibody sarilumab in severe COVID-19 pneumonia.

19 May 2020

Do parasites protect against SARS-CoV-2?

The world has rarely seen such a readily transmissible infection as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) over the last century. Within five months, the virus has created a Tsunami of COVID-19 positive cases, comprising almost 4.88 million people and causing 322,000 deaths.

19 May 2020

Does COVID-19 infect peripheral blood cells?

The emergence of the novel coronavirus outbreak in December 2019 was followed by its spread on a global scale unparalleled in the last 100 years. At present, it has claimed over 322,000 lives the world over, with over 4.88 million cases having tested positive.

19 May 2020

Did SARS-CoV-2 adapt to humans long before the index case?

A new study from Canada and the U.S. suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have already been pre-adapted to human transmission when it emerged in late 2019, which means there may be lingering populations of progenitor SARS-CoV-2 adept for human transmission and coronavirus disease (COVID-19) re-emergence. The research is published on the preprint server bioRxiv in May 2020.

19 May 2020

Sleep apnea may increase the risk of severe COVID-19, say researchers

An analysis conducted by researchers at the University of Turku and Turku University Hospital in Finland has suggested that obstructive sleep apnea (OSA) may be a risk factor for severe coronavirus disease 2019 (COVID-2019).

19 May 2020

No SARS-COV-2 among young children in Belgium attending daycare, report researchers

A study conducted by researchers in Belgium has found no evidence to support concerns that asymptomatic young children may be a source of severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) transmission.

19 May 2020

Common cytokine profile in ARDS, severe COVID-19 and sepsis

Many lives have been lost to the severe pneumonic disease COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), during the ongoing pandemic. The reason for the critical lung injury that results in a fatal outcome in a significant minority of patients has been supposed to be the dramatic oversecretion of pro-inflammatory cytokines and chemokines triggered by the virus.

19 May 2020

New animal model for COVID-19

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to ravage the world, scientists are frantically searching for a vaccine or new drug that will effectively counter the lethal effects of the virus that leads to COVID-19 disease.

19 May 2020

New UV disinfection technology is effective for deactivating SARS-CoV-2 on surfaces

Surfaces contaminated with SARS-CoV-2, the virus that causes COVID-19, pose a grave threat to the safety of healthcare workers, patients, frontline responders, military service members, cruise line passengers, hotel guests and people everywhere.

19 May 2020

Spraying disinfectants on streets can be harmful, WHO warns

The interim guidance released by the WHO aims to help health authorities formulate and implement policies on the disinfection of environmental surfaces during the coronavirus disease (COVID-19) pandemic.

18 May 2020

Countries back Australia's plan to investigate the coronavirus pandemic

Amid the coronavirus disease (COVID-19) pandemic, a coalition of 116 countries backs up a joint Australian and European Union plan to launch an independent inquiry into the coronavirus outbreak.

18 May 2020

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Patients infected with either severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 produce antibodies that bind to the other coronavirus, but the cross-reactive antibodies are not cross protective, at least in cell-culture experiments, researchers report May 17 in the journal Cell Reports.

18 May 2020

Tocilizumab improves survival in COVID-19 patients with ARDS

The current COVID-19 pandemic caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), has already nearly 4.8 million confirmed cases and more than 318,000 deaths.

18 May 2020

Common mutations in SARS-CoV-2 related to non-variable segments of structural proteins

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is thought to have originated from an animal species, most likely bats, which succeeded in crossing over to humans. However, the exact species of origin has not yet been confirmed.

18 May 2020

Potential new treatment approach to fatal COVID-19

Researchers from the University of Colorado Anschutz Medical Campus and Pathways Bioscience in the United States have found that activating a transcription factor involved in oxidative stress regulation, antiviral activity, and inflammation may serve as a new treatment approach to coronavirus disease 2019 (COVID-19).

18 May 2020

Novel insights on SARS-CoV-2 cell entry may inform further vaccine and treatment development

A research group from Harvard Medical School reported two cryo-electron microscopy structures derived from a single preparation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in their paper available on the preprint server bioRxiv. Understanding the nuances of prefusion and postfusion conformations shed light on viral cell entry and may, in turn, guide the development of vaccines and drugs.

18 May 2020